For example, potential effects on alcohol dependency are supported by a recent real-world population propensity-score-matched study of 83,825 patients with obesity, which showed that semaglutide, compared with other non-GLP-1-based obesity medications, was associated with a 50% lower risk for incident and recurrent alcohol use disorders over a 12-month period regardless of T2D status24. This evidence concerns the gene GCG and alcohol abuse.